{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:43:07Z","timestamp":1787236987669,"version":"build-2736575974"},"reference-count":38,"publisher":"American Diabetes Association","issue":"1","license":[{"start":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:00:00Z","timestamp":1635465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Phenotypic heterogeneity among patients with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease (ASCVD) is ill defined. We used cluster analysis machine-learning algorithms to identify phenotypes among trial participants with T2DM and ASCVD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>We used data from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) study (n = 14,671), a cardiovascular outcome safety trial comparing sitagliptin with placebo in patients with T2DM and ASCVD (median follow-up 3.0 years). Cluster analysis using 40 baseline variables was conducted, with associations between clusters and the primary composite outcome (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina) assessed by Cox proportional hazards models. We replicated the results using the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Four distinct phenotypes were identified: cluster I included Caucasian men with a high prevalence of coronary artery disease; cluster II included Asian patients with a low BMI; cluster III included women with noncoronary ASCVD disease; and cluster IV included patients with heart failure and kidney dysfunction. The primary outcome occurred, respectively, in 11.6%, 8.6%, 10.3%, and 16.8% of patients in clusters I to IV. The crude difference in cardiovascular risk for the highest versus lowest risk cluster (cluster IV vs. II) was statistically significant (hazard ratio 2.74 [95% CI 2.29\u20133.29]). Similar phenotypes and outcomes were identified in EXSCEL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>In patients with T2DM and ASCVD, cluster analysis identified four clinically distinct groups. Further cardiovascular phenotyping is warranted to inform patient care and optimize clinical trial designs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc20-2806","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T16:45:21Z","timestamp":1635525921000},"page":"204-212","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":61,"title":["Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine"],"prefix":"10.2337","volume":"45","clinical-trial-number":[{"clinical-trial-number":"nct00790205","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2346-8330","authenticated-orcid":false,"given":"Abhinav","family":"Sharma","sequence":"first","affiliation":[{"name":"1Division of Cardiology, McGill University, Montreal, Quebec, Canada"},{"name":"2Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinggan","family":"Zheng","sequence":"additional","affiliation":[{"name":"3Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin A.","family":"Ezekowitz","sequence":"additional","affiliation":[{"name":"2Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada"},{"name":"3Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia M.","family":"Westerhout","sequence":"additional","affiliation":[{"name":"3Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob A.","family":"Udell","sequence":"additional","affiliation":[{"name":"4Peter Munk Cardiac Centre, University Health Network and Women\u2019s College Hospital, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun G.","family":"Goodman","sequence":"additional","affiliation":[{"name":"3Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada"},{"name":"5St. Michael\u2019s Hospital, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"3Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9723-3876","authenticated-orcid":false,"given":"John B.","family":"Buse","sequence":"additional","affiliation":[{"name":"6School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer B.","family":"Green","sequence":"additional","affiliation":[{"name":"7Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Josse","sequence":"additional","affiliation":[{"name":"5St. Michael\u2019s Hospital, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith D.","family":"Kaufman","sequence":"additional","affiliation":[{"name":"8Merck & Co., Inc., Kenilworth, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6412-7989","authenticated-orcid":false,"given":"Darren K.","family":"McGuire","sequence":"additional","affiliation":[{"name":"9Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Ambrosio","sequence":"additional","affiliation":[{"name":"10School of Medicine, University of Perugia, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0978-2662","authenticated-orcid":false,"given":"Lee-Ming","family":"Chuang","sequence":"additional","affiliation":[{"name":"11Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[{"name":"7Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Peterson","sequence":"additional","affiliation":[{"name":"7Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1256-874X","authenticated-orcid":false,"given":"Rury R.","family":"Holman","sequence":"additional","affiliation":[{"name":"12Radcliffe Department of Medicine, University of Oxford, Oxford, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2021,10,29]]},"reference":[{"key":"2022051623180598300_B1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejheart.2006.05.014","article-title":"Systolic and diastolic heart failure: different phenotypes of the same disease?","volume":"9","author":"De Keulenaer","year":"2007","journal-title":"Eur J Heart Fail."},{"key":"2022051623180598300_B2","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1038\/ncomms5708","article-title":"A metabolic view on menopause and ageing","volume":"5","author":"Auro","year":"2014","journal-title":"Nat Commun"},{"key":"2022051623180598300_B3","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nmeth.3440","article-title":"Pathway and network analysis of cancer genomes","volume":"12","author":"Creixell","year":"2015","journal-title":"Nat Methods"},{"key":"2022051623180598300_B4","volume-title":"Committee on A Framework for Developing a New Taxonomy of Disease. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. 2011.","author":"National Research Council (US)","year":"2011"},{"key":"2022051623180598300_B5","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jchf.2019.11.005","article-title":"Distinct pathological pathways in patients with heart failure and diabetes","volume":"8","author":"Tromp","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2022051623180598300_B6","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S0140-6736(14)61889-4","article-title":"The war against heart failure: the Lancet lecture","volume":"385","author":"Braunwald","year":"2015","journal-title":"Lancet"},{"key":"2022051623180598300_B7","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.jchf.2018.05.020","article-title":"Glucose-lowering therapies to treat patients with heart failure and diabetes mellitus","volume":"6","author":"Sharma","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2022051623180598300_B8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"2022051623180598300_B9","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022051623180598300_B10","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1161\/CIRCULATIONAHA.119.041022","article-title":"Impact of regulatory guidance on evaluating cardiovascular risk of new glucose-lowering therapies to treat type 2 diabetes mellitus: lessons learned and future directions","volume":"141","author":"Sharma","year":"2020","journal-title":"Circulation"},{"key":"2022051623180598300_B11","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1001\/jama.2015.3595","article-title":"The precision medicine initiative: a new national effort","volume":"313","author":"Ashley","year":"2015","journal-title":"JAMA"},{"key":"2022051623180598300_B12","first-page":"592","article-title":"Patient clustering with uncoded text in electronic medical records","volume":"2013","author":"Henao","year":"2013","journal-title":"AMIA Annu Symp Proc"},{"key":"2022051623180598300_B13","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.jacc.2014.07.979","article-title":"Clinical implications of chronic heart failure phenotypes defined by cluster analysis","volume":"64","author":"Ahmad","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2022051623180598300_B14","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1161\/CIRCULATIONAHA.114.010637","article-title":"Phenomapping for novel classification of heart failure with preserved ejection fraction","volume":"131","author":"Shah","year":"2015","journal-title":"Circulation"},{"key":"2022051623180598300_B15","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jacc.2014.05.030","article-title":"Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study","volume":"64","author":"Lindman","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2022051623180598300_B16","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/ejhf.912","article-title":"A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure","volume":"19","author":"Sharma","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2022051623180598300_B17","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.ahj.2013.09.003","article-title":"Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease","volume":"166","author":"Green","year":"2013","journal-title":"Am Heart J"},{"key":"2022051623180598300_B18","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"2022051623180598300_B19","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"2022051623180598300_B20","volume-title":"Principal Component Analysis.","author":"Jolliffe","year":"2005"},{"key":"2022051623180598300_B21","doi-asserted-by":"crossref","first-page":"919425","DOI":"10.1155\/2012\/919425","article-title":"Metabolic syndrome derived from principal component analysis and incident cardiovascular events: the Multi Ethnic Study of Atherosclerosis (MESA) and Health, Aging, and Body Composition (Health ABC)","volume":"2012","author":"Agarwal","year":"2012","journal-title":"Cardiol Res Pract"},{"key":"2022051623180598300_B22","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2337\/dc17-1736","article-title":"Risk assessment in patients with diabetes with the TIMI risk score for atherothrombotic disease","volume":"41","author":"Bergmark","year":"2018","journal-title":"Diabetes Care"},{"key":"2022051623180598300_B23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/1476-511X-10-237","article-title":"A clustering analysis of lipoprotein diameters in the metabolic syndrome","volume":"10","author":"Frazier-Wood","year":"2011","journal-title":"Lipids Health Dis"},{"key":"2022051623180598300_B24","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/1741826711410821","article-title":"Asymmetrical distribution of atherosclerosis in the carotid artery: identical patterns across age, race, and gender","volume":"19","author":"Tajik","year":"2012","journal-title":"Eur J Prev Cardiol"},{"key":"2022051623180598300_B25","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.jcmg.2012.02.003","article-title":"Gender and the extent of coronary atherosclerosis, plaque composition, and clinical outcomes in acute coronary syndromes","volume":"5","author":"Lansky","year":"2012","journal-title":"JACC Cardiovasc Imaging"},{"key":"2022051623180598300_B26","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/archinte.168.5.451","article-title":"Development and validation of an all-cause mortality risk score in type 2 diabetes","volume":"168","author":"Yang","year":"2008","journal-title":"Arch Intern Med"},{"key":"2022051623180598300_B27","doi-asserted-by":"crossref","first-page":"d7163","DOI":"10.1136\/bmj.d7163","article-title":"Risk models and scores for type 2 diabetes: systematic review","volume":"343","author":"Noble","year":"2011","journal-title":"BMJ"},{"key":"2022051623180598300_B28","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/ejhf.1541","article-title":"Association of diabetes and kidney function according to age and systolic function with the incidence of sudden cardiac death and non-sudden cardiac death in myocardial infarction survivors with heart failure","volume":"21","author":"Coiro","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022051623180598300_B29","doi-asserted-by":"crossref","first-page":"e012797","DOI":"10.1161\/JAHA.119.012797","article-title":"Clinical and biomarker predictors of expanded heart failure outcomes in patients with type 2 diabetes after a recent acute coronary syndrome: insights from the EXAMINE trial","volume":"9","author":"Sharma","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2022051623180598300_B30","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/ejhf.327","article-title":"Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response","volume":"17","author":"Kao","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2022051623180598300_B31","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/CIRCULATIONAHA.114.014796","article-title":"Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) Registry","volume":"132","author":"Cavender","year":"2015","journal-title":"Circulation"},{"key":"2022051623180598300_B32","doi-asserted-by":"crossref","first-page":"e003892","DOI":"10.1161\/JAHA.116.003892","article-title":"International variation in outcomes among people with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: insights from the NAVIGATOR Trial","volume":"6","author":"Harumi Higuchi Dos Santos","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2022051623180598300_B33","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1042\/CS20000335","article-title":"The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56)","volume":"101","author":"Stevens","year":"2001","journal-title":"Clin Sci (Lond)"},{"key":"2022051623180598300_B34","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.amjcard.2019.01.034","article-title":"Patient phenotypes, cardiovascular risk, and ezetimibe treatment in patients after acute coronary syndromes (from IMPROVE-IT)","volume":"123","author":"Sharma","year":"2019","journal-title":"Am J Cardiol"},{"key":"2022051623180598300_B35","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/jamacardio.2016.0103","article-title":"Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus","volume":"1","author":"McGuire","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2022051623180598300_B36","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nrcardio.2012.123","article-title":"The many faces of heart failure with preserved ejection fraction","volume":"9","author":"Shah","year":"2012","journal-title":"Nat Rev Cardiol"},{"key":"2022051623180598300_B37","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2022051623180598300_B38","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1161\/CIRCULATIONAHA.119.041659","article-title":"Effect of once-weekly exenatide in patients with type 2 diabetes mellitus with and without heart failure and heart failure-related outcomes: insights from the EXSCEL trial","volume":"140","author":"Fudim","year":"2019","journal-title":"Circulation"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/45\/1\/204\/636281\/dc202806.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/45\/1\/204\/636281\/dc202806.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T19:18:34Z","timestamp":1652728714000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/45\/1\/204\/138975\/Cluster-Analysis-of-Cardiovascular-Phenotypes-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,29]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,10,29]]},"published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc20-2806","relation":{},"ISSN":["0149-5992"],"issn-type":[{"value":"0149-5992","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10,29]]}}}